|
1
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ikenoue T, Kanai F, Hikiba Y, Obata T,
Tanaka Y, Imamura J, Ohta M, Jazag A, Guleng B, Tateishi K, et al:
Functional analysis of PIK3CA gene mutations in human colorectal
cancer. Cancer Res. 65:4562–4567. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mizoguchi M, Nutt CL, Mohapatra G and
Louis DN: Genetic alterations of phosphoinositide 3-kinase subunit
genes in human glioblastomas. Brain Pathol. 14:372–377. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Samuels Y and Velculescu VE: Oncogenic
mutations of PIK3CA in human cancers. Cell Cycle. 3:1221–1224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Philp AJ, Campbell IG, Leet C, Vincan E,
Rockman SP, Whitehead RH, Thomas RJ and Phillips WA: The
phosphatidylinositol 3′-kinase p85alpha gene is an oncogene in
human ovarian and colon tumors. Cancer Res. 61:7426–7429.
2001.PubMed/NCBI
|
|
6
|
Cantley LC: The phosphoinositide 3-kinase
pathway. Science. 296:1655–1657. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Alessi DR, James SR, Downes CP, Holmes AB,
Gaffney PR, Reese CB and Cohen P: Characterization of a
3-phosphoinositide-dependent protein kinase which phosphorylates
and activates protein kinase Balpha. Curr Biol. 7:261–269. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Currie RA, Walker KS, Gray A, Deak M,
Casamayor A, Downes CP, Cohen P, Alessi DR and Lucocq J: Role of
phosphatidylinositol 3,4,5-trisphosphate in regulating the activity
and localization of 3-phosphoinositide-dependent protein kinase-1.
Biochem J. 337:575–583. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sarbassov DD, Guertin DA, Ali SM and
Sabatini DM: Phosphorylation and regulation of Akt/PKB by the
rictor-mTOR complex. Science. 307:1098–1101. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Engelman JA, Luo J and Cantley LC: The
evolution of phosphatidylinositol 3-kinases as regulators of growth
and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Duronio V: The life of a cell: Apoptosis
regulation by the PI3K/PKB pathway. Biochem J. 415:333–344. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Engelman JA, Chen L, Tan X, Crosby K,
Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y,
et al: Effective use of PI3K and MEK inhibitors to treat mutant
Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med.
14:1351–1356. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Serra V, Markman B, Scaltriti M, Eichhorn
PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S,
et al: NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K
signaling and inhibits the growth of cancer cells with activating
PI3K mutations. Cancer Res. 68:8022–8030. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
She QB, Chandarlapaty S, Ye Q, Lobo J,
Haskell KM, Leander KR, DeFeo-Jones D, Huber HE and Rosen N: Breast
tumor cells with PI3K mutation or HER2 amplification are
selectively addicted to Akt signaling. PLoS One. 3:e30652008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Junttila MR, Devasthali V, Cheng JH,
Castillo J, Metcalfe C, Clermont AC, Otter DD, Chan E, Bou-Reslan
H, Cao T, et al: Modeling targeted inhibition of MEK and PI3 kinase
in human pancreatic cancer. Mol Cancer Ther. 14:40–47. 2015.
View Article : Google Scholar
|
|
16
|
Duong HQ, Kim HJ, Kang HJ, Seong YS and
Bae I: ZSTK474, a PI3K inhibitor, suppresses proliferation and
sensitizes human pancreatic adenocarcinoma cells to gemcitabine.
Oncol Rep. 27:182–188. 2012.
|
|
17
|
Jung KH, Yan HH, Fang Z, Son MK, Lee H,
Hong S and Hong SS: HS-104, a PI3K inhibitor, enhances the
anticancer efficacy of gemcitabine in pancreatic cancer. Int J
Oncol. 45:311–321. 2014.PubMed/NCBI
|
|
18
|
Cruceru ML, Enciu AM, Popa AC, Albulescu
R, Neagu M, Tanase CP and Constantinescu SN: Signal transduction
molecule patterns indicating potential glioblastoma therapy
approaches. Onco Targets Ther. 6:1737–1749. 2013.PubMed/NCBI
|
|
19
|
Iwasaki I, Sugiyama H, Kanazawa S and
Hemmi H: Establishment of cisplatin-resistant variants of human
neuroblastoma cell lines, TGW and GOTO, and their drug
cross-resistance profiles. Cancer Chemother Pharmacol. 49:438–444.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maehara S, Tanaka S, Shimada M, Shirabe K,
Saito Y, Takahashi K and Maehara Y: Selenoprotein P, as a predictor
for evaluating gemcitabine resistance in human pancreatic cancer
cells. Int J Cancer. 112:184–189. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang Y, Kuramitsu Y, Tokuda K, Okada F,
Baron B, Akada J, Kitagawa T and Nakamura K: Proteomic analysis
indicates that overexpression and nuclear translocation of
lactoylglutathione lyase (GLO1) is associated with tumor
progression in murine fibrosarcoma. Electrophoresis. 35:2195–2202.
2014.PubMed/NCBI
|
|
22
|
Wang Y, Kuramitsu Y, Tokuda K, Baron B,
Kitagawa T, Akada J, Maehara S, Maehara Y and Nakamura K:
Gemcitabine induces poly (ADP-ribose) polymerase-1 (PARP-1)
degradation through autophagy in pancreatic cancer. PLoS One.
9:e1090762014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Choudhury GG, Mahimainathan L, Das F,
Venkatesan B and Ghosh-Choudhury N: c-Src couples PI 3 kinase/Akt
and MAPK signaling to PDGF-induced DNA synthesis in mesangial
cells. Cell Signal. 18:1854–1864. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Moelling K, Schad K, Bosse M, Zimmermann S
and Schweneker M: Regulation of Raf-Akt cross-talk. J Biol Chem.
277:31099–31106. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qi S, Xin Y, Qi Z, Xu Y, Diao Y, Lan L,
Luo L and Yin Z: HSP27 phosphorylation modulates TRAIL-induced
activation of Src-Akt/ERK signaling through interaction with
β-arrestin2. Cell Signal. 26:594–602. 2014. View Article : Google Scholar
|
|
26
|
Zheng C, Lin Z, Zhao ZJ, Yang Y, Niu H and
Shen X: MAPK-activated protein kinase-2 (MK2)-mediated formation
and phosphorylation-regulated dissociation of the signal complex
consisting of p38, MK2, Akt, and Hsp27. J Biol Chem.
281:37215–37226. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singh S, Srivastava SK, Bhardwaj A, Owen
LB and Singh AP: CXCL12-CXCR4 signalling axis confers gemcitabine
resistance to pancreatic cancer cells: A novel target for therapy.
Br J Cancer. 103:1671–1679. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Ma J, Ma Q, Li B, Han L, Liu J, Xu
Q, Duan W, Yu S, Wang F, et al: Resveratrol inhibits the
epithelial-mesenchymal transition of pancreatic cancer cells via
suppression of the PI-3K/Akt/NF-κB pathway. Curr Med Chem.
20:4185–4194. 2013. View Article : Google Scholar
|
|
29
|
Fujiwara M, Izuishi K, Sano T, Hossain MA,
Kimura S, Masaki T and Suzuki Y: Modulating effect of the
PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic
cancer cells. J Exp Clin Cancer Res. 27:762008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mori-Iwamoto S, Kuramitsu Y, Ryozawa S,
Taba K, Fujimoto M, Okita K, Nakamura K and Sakaida I: A proteomic
profiling of gemcitabine resistance in pancreatic cancer cell
lines. Mol Med Rep. 1:429–434. 2008.PubMed/NCBI
|
|
31
|
Vlahos CJ, Matter WF, Hui KY and Brown RF:
A specific inhibitor of phosphatidylinositol 3-kinase,
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol
Chem. 269:5241–5248. 1994.PubMed/NCBI
|
|
32
|
Toledo LM, Lydon NB and Elbaum D: The
structure-based design of ATP-site directed protein kinase
inhibitors. Curr Med Chem. 6:775–805. 1999.PubMed/NCBI
|
|
33
|
Grandage VL, Gale RE, Linch DC and Khwaja
A: PI3-kinase/Akt is constitutively active in primary acute myeloid
leukaemia cells and regulates survival and chemoresistance via
NF-kappaB, Mapkinase and p53 pathways. Leukemia. 19:586–594.
2005.PubMed/NCBI
|
|
34
|
Ohnishi K, Yasumoto J, Takahashi A and
Ohnishi T: LY294002, an inhibitor of PI-3K, enhances heat
sensitivity independently of p53 status in human lung cancer cells.
Int J Oncol. 29:249–253. 2006.PubMed/NCBI
|
|
35
|
Walker EH, Pacold ME, Perisic O, Stephens
L, Hawkins PT, Wymann MP and Williams RL: Structural determinants
of phosphoinositide 3-kinase inhibition by wortmannin, LY294002,
quercetin, myricetin, and staurosporine. Mol Cell. 6:909–919. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shtivelman E, Sussman J and Stokoe D: A
role for PI 3-kinase and PKB activity in the G2/M phase of the cell
cycle. Curr Biol. 12:919–924. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xing C, Zhu B, Liu H, Yao H and Zhang L:
Class I phosphatidylinositol 3-kinase inhibitor LY294002 activates
autophagy and induces apoptosis through p53 pathway in gastric
cancer cell line SGC7901. Acta Biochim Biophys Sin (Shanghai).
40:194–201. 2008. View Article : Google Scholar
|
|
38
|
Lee YK and Park OJ: Regulation of mutual
inhibitory activities between AMPK and Akt with quercetin in MCF-7
breast cancer cells. Oncol Rep. 24:1493–1497. 2010.PubMed/NCBI
|
|
39
|
Bakin AV, Tomlinson AK, Bhowmick NA, Moses
HL and Arteaga CL: Phosphatidylinositol 3-kinase function is
required for transforming growth factor beta-mediated epithelial to
mesenchymal transition and cell migration. J Biol Chem.
275:36803–36810. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Van de Sande T, De Schrijver E, Heyns W,
Verhoeven G and Swinnen JV: Role of the phosphatidylinositol
3′-kinase/PTEN/Akt kinase pathway in the overexpression of fatty
acid synthase in LNCaP prostate cancer cells. Cancer Res.
62:642–646. 2002.PubMed/NCBI
|
|
41
|
Cole GW Jr, Alleva AM, Zuo JT, Sehgal SS,
Yeow WS, Schrump DS and Nguyen DM: Suppression of pro-metastasis
phenotypes expression in malignant pleural mesothelioma by the PI3K
inhibitor LY294002 or the MEK inhibitor UO126. Anticancer Res.
26A:809–821. 2006.
|
|
42
|
Yi XP, Han T, Li YX, Long XY and Li WZ:
Simultaneous silencing of XIAP and survivin causes partial
mesenchymal-epithelial transition of human pancreatic cancer cells
via the PTEN/PI3K/Akt pathway. Mol Med Rep. 12:601–608.
2015.PubMed/NCBI
|
|
43
|
Strouch MJ, Milam BM, Melstrom LG, McGill
JJ, Salabat MR, Ujiki MB, Ding XZ and Bentrem DJ: The flavonoid
apigenin potentiates the growth inhibitory effects of gemcitabine
and abrogates gemcitabine resistance in human pancreatic cancer
cells. Pancreas. 38:409–415. 2009. View Article : Google Scholar : PubMed/NCBI
|
